Sonnet BioTherapeutics Holdings, Inc. (SONN)
NASDAQ: SONN · Real-Time Price · USD
1.540
0.00 (0.00%)
At close: Jan 21, 2025, 4:00 PM
1.520
-0.020 (-1.30%)
After-hours: Jan 21, 2025, 7:12 PM EST
SONN Employees
Sonnet BioTherapeutics Holdings had 13 employees as of September 30, 2024. The number of employees increased by 1 or 8.33% compared to the previous year.
Employees
13
Change (1Y)
1
Growth (1Y)
8.33%
Revenue / Employee
$1,433
Profits / Employee
-$572,095
Market Cap
4.63M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
SONN News
- 4 weeks ago - Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment - GlobeNewsWire
- 5 weeks ago - Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 6 weeks ago - Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial - GlobeNewsWire
- 6 weeks ago - Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action - GlobeNewsWire
- 2 months ago - Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment - GlobeNewsWire
- 2 months ago - Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 2 months ago - Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates - GlobeNewsWire